Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study of SYH2053 Injection in Participants With Hepatic Impairment Compared to Participants With Normal Hepatic Function

A Phase I Clinical Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of SYH2053 Injection in Participants With Mild Hepatic Impairment (Child-Pugh Class A), Moderate Hepatic Impairment (Child-Pugh Class B), and Normal Hepatic Function.

This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of SYH2053 injection in participants with mild, and moderate hepatic impairment compared to participants with normal hepatic function.

Panoramica dello studio

Stato

Reclutamento

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

24

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Clinical Trials Information Group NA officer
  • Numero di telefono: 86-0311-69085587
  • Email: ctr-contact@cspc.cn

Luoghi di studio

    • Shandong
      • Jinan, Shandong, Cina, 250014
        • Reclutamento
        • the First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
        • Contatto:
          • wei zhao Chief pharmacist, Pharmaciae Doctor
          • Numero di telefono: CN 0531-89268212
          • Email: zhao4wei2@hotmail.com

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Aged between 18 and 75 years (inclusive), males or females.
  • Body weight ≥ 45.0 kg for females or ≥ 50.0 kg for males, and body mass index (BMI) between 18 and 32 kg/m² (inclusive), where BMI = weight (kg) / height² (m²).
  • LDL-C ≥ 70 mg/dL (1.8 mmol/L) at the screening visit.
  • Participants must be able to communicate well with the investigator and be willing and able to comply with all protocol requirements throughout the study.
  • For participants with hepatic impairment: patients with chronic hepatic impairment or cirrhosis caused by primary liver diseases (e.g., viral hepatitis, alcoholic liver disease, autoimmune hepatitis, etc.), classified as Child-Pugh Class A or B at screening; and judged by the investigator to have stable disease status for at least 1 month based on clinical presentation and other findings.
  • For participants with hepatic impairment: stable treatment for hepatic impairment, its complications, and other concomitant diseases for at least 1 month prior to study drug administration, with no anticipated dose adjustments needed during the study.
  • For participants with hepatic impairment: except for hepatic insufficiency and its complications, the subject's physical condition is deemed acceptable based on assessments of vital signs, physical examination, laboratory tests, 12-lead electrocardiogram, chest X-ray, ultrasound examination, and routine electroencephalogram.
  • For participants with normal hepatic function: subjects are matched to participants in the hepatic insufficiency group by body weight (within ±10 kg), age (within ±10 years), and sex, allowing a sex count difference of up to ±1 between the two groups.
  • For participants with normal hepatic function: physical examination, vital signs, laboratory tests, 12-lead electrocardiogram, chest X-ray, and ultrasound examination show results that are either normal or abnormal but without clinical significance.

Exclusion Criteria:

  • History of severe allergic reactions, including but not limited to anaphylactic shock and severe generalized urticaria, or documented hypersensitivity to oligonucleotide-based therapeutics.
  • Initiation of or unstable use of lipid-lowering agents, or drugs or supplements with lipid-modulating effects as determined by the investigator, within 30 days prior to screening, including but not limited to statins, fibrates, ezetimibe/hyzetimibe, red yeast rice, niacin, omega-3 fatty acids, stanols, or bile acid sequestrants; use of PCSK9 monoclonal antibodies or oral PCSK9 inhibitors within 180 days prior to screening; or use of Leqvio® (inclisiran) or any other RNA-based therapy for lipid-lowering purposes within 2 years prior to screening, including but not limited to siRNA or antisense oligonucleotide therapy.
  • Participation in any clinical trial and receipt of investigational drug within 5 half-lives of the study drug or within 90 days prior to screening (whichever is longer), or plan to participate in any other clinical trial during the study period.
  • Average daily smoking of more than 5 cigarettes (or equivalent tobacco in e-cigarettes) within 3 months prior to screening, and/or unwillingness to refrain from using any tobacco products during the study period.
  • Subjects with habitual alcohol use within 6 months prior to screening, defined as consumption of more than 14 units of alcohol per week (1 unit = 360 mL of beer [5% alcohol], 45 mL of spirits [40% alcohol], or 150 mL of wine [12% alcohol]); and/or those who are unable to refrain from alcohol consumption during the study period; and/or those with a positive breath alcohol test at screening.
  • History of drug abuse, and/or a positive urine drug screening test.
  • Daily consumption of excessive tea, coffee, and/or caffeinated beverages (8 cups or more per day, 1 cup = 250 mL) within 1 month prior to screening, and/or unwillingness to refrain from consuming tea, coffee, and/or caffeinated foods, grapefruit (pomelo) and/or grapefruit juice, and/or poppy seed-containing products during the study period.
  • Blood loss or blood donation exceeding 200 mL within 3 months prior to screening, and/or platelet donation within 2 weeks prior to screening, or planned blood donation during the study period.
  • Pregnant or lactating women; female participants of childbearing potential with a serum pregnancy test result exceeding the upper limit of normal at screening; or female participants who had unprotected sexual intercourse within 2 weeks prior to screening.
  • Planned pregnancy (including sperm donation or egg donation) from the signing of the informed consent form (ICF) until 6 months after study drug administration, and/or unwillingness to adopt effective non-pharmacological contraceptive methods.
  • Any other condition that, in the investigator's opinion, makes the participant unsuitable for participation in this clinical trial.
  • For participants with hepatic impairment: active hepatitis B or hepatitis C at screening.
  • For participants with hepatic impairment: subjects who meet any of the following criteria at screening and/or baseline (if applicable) are excluded: a) Positive for HIV antibody or syphilis antibody; b) Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², calculated using the CKD-EPI formula; c) Glycated hemoglobin (HbA1c) > 8.5%; d) Systolic blood pressure (SBP) ≥ 160 mmHg or diastolic blood pressure (DBP) ≥ 100 mmHg; e) Platelet count < 20 × 10⁹/L; f) Hemoglobin < 80 g/L.
  • For participants with hepatic impairment: drug-induced liver injury; history of liver transplantation; hepatorenal syndrome.
  • For participants with hepatic impairment: acute hepatic injury from any cause within 2 months prior to screening.
  • For participants with hepatic impairment: severe ascites or pleural effusion requiring paracentesis or drainage.
  • For participants with hepatic impairment: diseases affecting bile excretion, such as biliary cirrhosis, biliary obstruction, or cholestatic liver disease.
  • For participants with hepatic impairment: severe portal hypertension or prior portosystemic shunt surgery, including transjugular intrahepatic portosystemic shunt (TIPS).
  • For participants with hepatic impairment: hepatic failure at screening, or cirrhosis complicated by hepatic encephalopathy, hepatocellular carcinoma, esophageal or gastric variceal bleeding, or other complications deemed unsuitable by the investigator.
  • For participants with hepatic impairment: any current or prior (within 24 weeks prior to screening) clinical disease involving the circulatory, endocrine, neuropsychiatric, digestive, respiratory, hematologic, or urinary systems that, in the investigator's assessment, makes the participant unsuitable for participation in the trial.
  • For participants with normal hepatic function: use of any medication within 14 days or 5 half-lives (whichever is longer) prior to dosing (with the exception of topical preparations exerting local effects).
  • For participants with normal hepatic function: positive for hepatitis B surface antigen, hepatitis C virus antibody, HIV antibody, or syphilis antibody.
  • For participants with normal hepatic function: any current or prior (within 24 weeks prior to screening) severe or chronic disease involving the circulatory, endocrine, neuropsychiatric, digestive, respiratory, hematologic, or urinary systems, or any other disease that may interfere with the trial results.
  • For participants with normal hepatic function: physical examination and/or laboratory findings at screening suggesting the presence or potential presence of hepatic impairment.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: SYH2053 (normal hepatic function)

SYH2053 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Sperimentale: SYH2053 (mild hepatic function)

SYH2053 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Sperimentale: SYH2053 (moderate hepatic function)

SYH2053 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Amount excreted unchanged in urine (Ae) of SYH2053 over 72 hours post-dose
Lasso di tempo: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Fraction excreted (fe) of SYH2053 over 72 hours post-dose
Lasso di tempo: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Renal clearance (CLr) of SYH2053
Lasso di tempo: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Maximum observed plasma concentration (Cmax)
Lasso di tempo: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Area under the curve of the plasma concentration (AUC) from time 0 to the last measurable time (AUC0-t) and from time 0 extrapolated to infinity (AUC0-inf)
Lasso di tempo: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Time to reach maximum plasma concentration (Tmax) and terminal half-life (t1/2).
Lasso di tempo: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Pharmacokinetics: Apparent total clearance (CL/F)
Lasso di tempo: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Pharmacokinetics: Apparent volume of distribution (Vz/F)
Lasso di tempo: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
The serum Low-density lipoprotein cholesterol (LDL-C) level
Lasso di tempo: 6 months
6 months
The serum PCSK9 level
Lasso di tempo: 6 months
6 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

15 agosto 2026

Completamento primario (Stimato)

15 agosto 2027

Completamento dello studio (Stimato)

15 settembre 2027

Date di iscrizione allo studio

Primo inviato

11 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

11 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • SYH2053-008

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi